Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25588735

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

Author
GUTSTEIN, D. E1 ; KRISHNA, R1 ; JOHNS, D1 ; SURKS, H. K1 ; DANSKY, H. M1 ; SHAH, S1 ; MITCHEL, Y. B1 ; ARENA, J1 ; WAGNER, J. A1
[1] Merck Sharp & Dohme Corp., Rahway, New Jersey, United States
Source

Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 109-122, 14 p ; ref : 92 ref

CODEN
CLPTAT
ISSN
0009-9236
Scientific domain
Pharmacology drugs
Publisher
Nature Publishing Group, Basingstoke
Publication country
United Kingdom
Document type
Article
Language
English
Keyword (fr)
Antibactérien Antibiotique Homme Hypolipémiant Inhibiteur Pathologie de l'appareil circulatoire Risque cardiovasculaire Anacétrapib Dérivé de l'oxazolidinone
Keyword (en)
Antibacterial agent Antibiotic Human Antilipemic agent Inhibitor Cardiovascular disease Cardiovascular risk Oxazolidinone derivative
Keyword (es)
Antibacteriano Antibiótico Hombre Hipolipemiante Inhibidor Aparato circulatorio patología Riesgo cardiovascular Oxazolidinona derivado
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments

Discipline
General pharmacology
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
25588735

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web